T Cell Activation Inhibitor, Pharmaceutical Composition Containing Same, And Screening Method For T Cell Activation Inhibiting Substance


Ontology type: sgo:Patent     


Patent Info

DATE

2011-06-16T00:00

AUTHORS

山下 俊英 , 久保 武一

ABSTRACT

Disclosed is a T cell activation inhibitor which contains an RGM inhibiting substance such as an anti-RGM neutralizing antibody. The T cell activation inhibitor is useful as a pharmaceutical composition for prevention or treatment of autoimmune diseases including multiple sclerosis and other diseases caused by the activation of T cells. In addition, screening for a T cell activation inhibiting substance can be performed by bringing substances to be tested into contact with an RGM and selecting a substance that reduces the activity level of the RGM. More... »

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2581", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "name": "\u5c71\u4e0b\u3000\u4fca\u82f1", 
        "type": "Person"
      }, 
      {
        "name": "\u4e45\u4fdd \u6b66\u4e00", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1016/j.conb.2006.12.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000608064"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1083/jcb.200508143", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006004525"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0896-6273(90)90227-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008630158"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/40187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014459412", 
          "https://doi.org/10.1038/40187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/40187", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014459412", 
          "https://doi.org/10.1038/40187"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.bbrc.2009.03.115", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017687229"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/gene.2009.111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026226405", 
          "https://doi.org/10.1038/gene.2009.111"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/gene.2009.111", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026226405", 
          "https://doi.org/10.1038/gene.2009.111"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ni765", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028631372", 
          "https://doi.org/10.1038/ni765"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ni765", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028631372", 
          "https://doi.org/10.1038/ni765"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1098/rstb.2006.1888", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030983476"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1128/mcb.22.4.1001-1015.2002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032515124"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/107385849900500107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036699064"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/107385849900500107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036699064"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2011-06-16T00:00", 
    "description": "

Disclosed is a T cell activation inhibitor which contains an RGM inhibiting substance such as an anti-RGM neutralizing antibody. The T cell activation inhibitor is useful as a pharmaceutical composition for prevention or treatment of autoimmune diseases including multiple sclerosis and other diseases caused by the activation of T cells. In addition, screening for a T cell activation inhibiting substance can be performed by bringing substances to be tested into contact with an RGM and selecting a substance that reduces the activity level of the RGM.

", "id": "sg:patent.WO-2011071059-A1", "keywords": [ "T cell activation", "pharmaceutical", "screening method", "substance", "antibody", "prevention", "autoimmune disease", "multiple sclerosis", "disease", "T cell", "Mass Screening", "activity level" ], "name": "T CELL ACTIVATION INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND SCREENING METHOD FOR T CELL ACTIVATION INHIBITING SUBSTANCE", "recipient": [ { "id": "https://www.grid.ac/institutes/grid.136593.b", "type": "Organization" }, { "id": "https://www.grid.ac/institutes/grid.136304.3", "type": "Organization" } ], "sameAs": [ "https://app.dimensions.ai/details/patent/WO-2011071059-A1" ], "sdDataset": "patents", "sdDatePublished": "2019-04-18T10:07", "sdLicense": "https://scigraph.springernature.com/explorer/license/", "sdPublisher": { "name": "Springer Nature - SN SciGraph project", "type": "Organization" }, "sdSource": "s3://com-uberresearch-data-patents-target-20190320-rc/data/sn-export/402f166718b70575fb5d4ffe01f064d1/0000100128-0000352499/json_export_00208.jsonl", "type": "Patent" } ]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/patent.WO-2011071059-A1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/patent.WO-2011071059-A1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/patent.WO-2011071059-A1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/patent.WO-2011071059-A1'


 

This table displays all metadata directly associated to this object as RDF triples.

73 TRIPLES      15 PREDICATES      37 URIs      20 LITERALS      2 BLANK NODES

Subject Predicate Object
1 sg:patent.WO-2011071059-A1 schema:about anzsrc-for:2581
2 schema:author N66902401e1764e38957957d0e789d8ae
3 schema:citation sg:pub.10.1038/40187
4 sg:pub.10.1038/gene.2009.111
5 sg:pub.10.1038/ni765
6 https://doi.org/10.1016/0896-6273(90)90227-7
7 https://doi.org/10.1016/j.bbrc.2009.03.115
8 https://doi.org/10.1016/j.conb.2006.12.001
9 https://doi.org/10.1083/jcb.200508143
10 https://doi.org/10.1098/rstb.2006.1888
11 https://doi.org/10.1128/mcb.22.4.1001-1015.2002
12 https://doi.org/10.1177/107385849900500107
13 schema:datePublished 2011-06-16T00:00
14 schema:description <p>Disclosed is a T cell activation inhibitor which contains an RGM inhibiting substance such as an anti-RGM neutralizing antibody. The T cell activation inhibitor is useful as a pharmaceutical composition for prevention or treatment of autoimmune diseases including multiple sclerosis and other diseases caused by the activation of T cells. In addition, screening for a T cell activation inhibiting substance can be performed by bringing substances to be tested into contact with an RGM and selecting a substance that reduces the activity level of the RGM.</p>
15 schema:keywords Mass Screening
16 T cell
17 T cell activation
18 activity level
19 antibody
20 autoimmune disease
21 disease
22 multiple sclerosis
23 pharmaceutical
24 prevention
25 screening method
26 substance
27 schema:name T CELL ACTIVATION INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND SCREENING METHOD FOR T CELL ACTIVATION INHIBITING SUBSTANCE
28 schema:recipient https://www.grid.ac/institutes/grid.136304.3
29 https://www.grid.ac/institutes/grid.136593.b
30 schema:sameAs https://app.dimensions.ai/details/patent/WO-2011071059-A1
31 schema:sdDatePublished 2019-04-18T10:07
32 schema:sdLicense https://scigraph.springernature.com/explorer/license/
33 schema:sdPublisher N19f8ebecd7024b8e9335e14577ee0e5a
34 sgo:license sg:explorer/license/
35 sgo:sdDataset patents
36 rdf:type sgo:Patent
37 N19f8ebecd7024b8e9335e14577ee0e5a schema:name Springer Nature - SN SciGraph project
38 rdf:type schema:Organization
39 N66902401e1764e38957957d0e789d8ae rdf:first N74672f1c30af4ebf881838e6f60d3569
40 rdf:rest Nae260f89d9fb4116b3db1e21a0a42a20
41 N74672f1c30af4ebf881838e6f60d3569 schema:name 山下 俊英
42 rdf:type schema:Person
43 N75acfbb7b75e41d5a1320d3a2b3f8167 schema:name 久保 武一
44 rdf:type schema:Person
45 Nae260f89d9fb4116b3db1e21a0a42a20 rdf:first N75acfbb7b75e41d5a1320d3a2b3f8167
46 rdf:rest rdf:nil
47 anzsrc-for:2581 schema:inDefinedTermSet anzsrc-for:
48 rdf:type schema:DefinedTerm
49 sg:pub.10.1038/40187 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014459412
50 https://doi.org/10.1038/40187
51 rdf:type schema:CreativeWork
52 sg:pub.10.1038/gene.2009.111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026226405
53 https://doi.org/10.1038/gene.2009.111
54 rdf:type schema:CreativeWork
55 sg:pub.10.1038/ni765 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028631372
56 https://doi.org/10.1038/ni765
57 rdf:type schema:CreativeWork
58 https://doi.org/10.1016/0896-6273(90)90227-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008630158
59 rdf:type schema:CreativeWork
60 https://doi.org/10.1016/j.bbrc.2009.03.115 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017687229
61 rdf:type schema:CreativeWork
62 https://doi.org/10.1016/j.conb.2006.12.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000608064
63 rdf:type schema:CreativeWork
64 https://doi.org/10.1083/jcb.200508143 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006004525
65 rdf:type schema:CreativeWork
66 https://doi.org/10.1098/rstb.2006.1888 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030983476
67 rdf:type schema:CreativeWork
68 https://doi.org/10.1128/mcb.22.4.1001-1015.2002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032515124
69 rdf:type schema:CreativeWork
70 https://doi.org/10.1177/107385849900500107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036699064
71 rdf:type schema:CreativeWork
72 https://www.grid.ac/institutes/grid.136304.3 schema:Organization
73 https://www.grid.ac/institutes/grid.136593.b schema:Organization
 




Preview window. Press ESC to close (or click here)


...